NYSE:JNJ

Johnson & Johnson - JNJ Stock Forecast, Price & News

$162.00

-6.23 (-3.70%)

(As of 01/30/2023 12:00 AM ET)

Add

Compare

Today's Range: $161.08
▼
$168.54
50-Day Range: $168.23
▼
$180.25
52-Week Range: $155.72
▼
$186.69

Volume: 23.18 million shs
Average Volume: 6.28 million shs
Market Capitalization: $423.55 billion

P/E Ratio: 24.04
Dividend Yield: 2.69%
Price Target: $182.75

Institutional Ownership

Johnson & Johnson MarketRank™ Forecast

Analyst Rating: Hold
2.42 Rating Score
Upside/Downside: 12.8% Upside
$182.75 Price Target
Short Interest: Healthy
0.32% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -1.98
Upright™ Environmental Score
News Sentiment: 0.50
Based on 75 Articles This Week
Insider Trading: Selling Shares
$40.96 M Sold Last Quarter
Proj. Earnings Growth: 3.81%
From $10.51 to $10.91 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.25 out of 5 stars

Medical Sector

4th out of 1,055 stocks

Pharmaceutical Preparations Industry

3rd out of 518 stocks

3.2

Analyst's Opinion

Consensus Rating
Johnson & Johnson has received a consensus rating of Hold. The company's average rating score is 2.42, and is based on 5 buy ratings, 7 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $182.75, Johnson & Johnson has a forecasted upside of 12.8% from its current price of $162.00.
Amount of Analyst Coverage
Johnson & Johnson has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
0.32% of the float of Johnson & Johnson has been sold short.
Short Interest Ratio / Days to Cover
Johnson & Johnson has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Johnson & Johnson has recently decreased by 15.13%, indicating that investor sentiment is improving significantly.

4.2

Dividend Strength

Dividend Yield
Johnson & Johnson pays a meaningful dividend of 2.69%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Johnson & Johnson has been increasing its dividend for 61 years.
Dividend Coverage
The dividend payout ratio of Johnson & Johnson is 67.06%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 41.43% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Johnson & Johnson has received a 52.68% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Ustekinumab", "Clinical research services for physical health", "Rivaroxaban", "Daratumumab", "Ibrutinib", and "HIV medication" products. See details.
Environmental Sustainability
The Environmental Impact score for Johnson & Johnson is -1.98.

3.6

News and Social Media Coverage

News Sentiment
Johnson & Johnson has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 75 news articles for Johnson & Johnson this week, compared to 21 articles on an average week.
Social Mentions This Week
MarketBeat has tracked 6 reddit mentions for Johnson & Johnson this week, compared to 3 mentions on an average week.
Search Interest
294 people have searched for JNJ on MarketBeat in the last 30 days. This is an increase of 97% compared to the previous 30 days.
MarketBeat Follows
100 people have added Johnson & Johnson to their MarketBeat watchlist in the last 30 days. This is an increase of 23% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Johnson & Johnson insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $40,960,735.00 in company stock.
Percentage Held by Insiders
Only 0.35% of the stock of Johnson & Johnson is held by insiders.
Percentage Held by Institutions
67.94% of the stock of Johnson & Johnson is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Johnson & Johnson are expected to grow by 3.81% in the coming year, from $10.51 to $10.91 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Johnson & Johnson is 24.04, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.58.
Price to Earnings Ratio vs. Sector
The P/E ratio of Johnson & Johnson is 24.04, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 97.46.
Price to Earnings Growth Ratio
Johnson & Johnson has a PEG Ratio of 2.90. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Johnson & Johnson has a P/B Ratio of 5.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Johnson & Johnson (NYSE:JNJ) Stock

Johnson & Johnson is a US-based multinational pharmaceutical company that started in the early 1870s. Robert Wood Johnson began training as a pharmacist at 16 and founded his 1st company in 1873. That company would be disbanded by 1886 when Johnson joined his brothers to form today's entity. The company’s first line of products was sterile surgical dressings which were soon followed up by household products and medical guides.

Today, Johnson & Johnson is one of the world’s largest companies. It is ranked 36th on the 2021 Fortune 500 list and is a Dow Jones Industrial Average member. The company operates via 250 subsidiaries with operations in 60 countries and product sales in 175. As of 2021, annual sales were in the range of $95 billion and growing. The company is also a leader in equality and the advancement of women’s rights. Johnson & Johnson’s workforce was nearly 50% female by 1910, and many held significant positions of responsibility.

Among the company’s many advances in health care is the advancement of sterile conditions to prevent postoperative and secondary infections. Products include sterile gauze, cotton and dressings, and the development of the industrial sterilization process. However, the product that launched the company to success was the combination of a sterile dressing with tape. The company called the new products Band-Aids, which is now synonymous with small, prepackaged bandages. Another major win for the company was Johnson & Johnson Baby Soap.

Today, Johnson & Johnson operates in 3 segments: Pharmaceutical, Consumer Health and MedTech. The Consumer Health segment alone covers brands like Aveeno, Listerine, Tylenol, Zyrtec, Band-Aid and Neosporin, which are among the world’s most recognizable brands. The company’s purpose is to “blend science and ingenuity to change the trajectory of health for humanity profoundly”.

The Pharmaceutical segment offers products in all segments of the healthcare spectrum and has partnerships to develop new drugs with at least 10 other major healthcare providers and dozens of smaller research facilities. Products are offered wholesale to retailers and through healthcare systems. The MedTech segment develops and manufactures various healthcare devices and diagnostic tools. Among the many recognizable products from this segment are ACUVUE contact lenses.

Johnson & Johnson went public in 1944 and began paying dividends soon after. The company began increasing its dividend payment in 1962 and has increased it yearly. The company is a member of the Dividend Aristocrat Index and qualifies as a Dividend King with more than 50 years of consecutive annual increases. The company employs more than 142,000 individuals and serves more than 1 billion daily. Regarding the company’s health, its track record of dividend payments is backed up by a AAA credit rating. Johnson & Johnson is one of only 2 US corporations with such a rating and is more trusted than the US government.

The company announced plans to split into two publicly traded companies in 2021. The move is expected to be complete in late 2023 and will result in a Consumer Health company and a Pharmaceutical company.

Receive JNJ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.

JNJ Stock News Headlines

January 30, 2023 | dividendstocks.com

AbbVie Stock: Dividend King ABBV Overview (JNJ)

January 26, 2023 | marketbeat.com

Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?

Johnson & Johnson and Abbott Laboratories are 2 dividend kings guiding for growth in 2023 and are on track to increase their yield yet again.

January 31, 2023 | PressReach (Ad)

Top Lithium Stock

Today's stock market report features a battery metal lithium stock with great potential.

January 25, 2023 | marketbeat.com

How Will Early 2023 Layoffs Affect These 5 Biotech Stocks? (JNJ)

Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.

January 24, 2023 | marketbeat.com

J&J tops 4Q earnings forecasts as profit, revenue slip

Johnson & Johnson beat earnings expectations in the final quarter of 2022 even as a strong dollar and sinking COVID-19 vaccine sales hurt revenue

January 21, 2023 | marketbeat.com

MarketBeat Week in Review – 1/16 - 1/20 (JNJ)

The shortened trading week looks to be ending on a sour note over growing recession fears. Here are some of the top stories from our MarketBeat contributors

January 20, 2023 | marketbeat.com

J&J subsidiary to pay $9.75M to resolve kickback allegations

Federal prosecutors say a subsidiary of health care company Johnson & Johnson has agreed to pay nearly $10 million to settle allegations that it violated federal and state law by providing free products to a surgeon

January 18, 2023 | marketbeat.com

Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?

Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week.

January 31, 2023 | PressReach (Ad)

Top Lithium Stock

Today's stock market report features a battery metal lithium stock with great potential.

January 17, 2023 | marketbeat.com

3 Dividend Stocks For Passive Income (JNJ)

I'm aiming to grow my passive income this year through adding these safe value stocks to my portfolio that have strong dividend yields.

January 4, 2023 | marketbeat.com

MarketBeat: Week in Review 12/05 – 12/09 (JNJ)

The markets continue to have a lot to digest before there can be a Santa Claus rally. Here are some of the top stories our analysts were covering this week.

January 31, 2023 | rttnews.com

Court Rejects J&J Bankruptcy Petition To End Talc Cancer Lawsuits

January 30, 2023 | msn.com

Johnson & Johnson, Chevron share losses lead Dow's 261-point drop

January 30, 2023 | fool.com

Why Johnson & Johnson Stock Slipped by Nearly 4% on Monday

January 30, 2023 | msn.com

Dow's 169-point fall led by losses for shares of Johnson & Johnson, Chevron

January 30, 2023 | msn.com

Hot Stocks: JNJ, MMM fall on legal decision; GEHC rises on earnings; PHG climbs

January 30, 2023 | barrons.com

Johnson & Johnson Shares Drop as Court Rejects Use of Bankruptcy in Talc Lawsuits

January 30, 2023 | stocknews.com

2 Stocks That Can Create Lasting Generational Wealth

January 30, 2023 | msn.com

3M declines suddenly after Johnson & Johnson loses appeal on talc litigation